{"product_id":"cancer-consult-expertise-for-clinical-practice-paperback-softback-9781118589212","title":"Cancer Consult; Expertise for Clinical Practice (Paperback \/ softback) 9781118589212","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eCancer Consult\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003eExpertise for Clinical Practice\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eSyed A. Abutalib (Edited by), SA Abutalib (Author), Maurie Markman (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781118589212, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003ePaperback \/ softback, published 22 August 2014\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e968 pages\u003cbr\u003e27.9 x 21.6 x 3.8 cm, 2.413 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eThe field of oncology benefits from several large-scale reference books and a host of monographs dedicated to specific cancers. However, truly excellent practice and review books are, surprisingly, quite scarce. Outside of a scant handful of books and online reference tools that offer clinical response practice and board review in a basic question and answer format, there are no resources that offer a robust, engaging, fully referenced tool for these vital activities in every oncologist’s and oncology trainee’s work. This print and electronic book seeks to fill that void, offering comprehensive question-and-answer style content that covers the entire specialty of oncology and provides practicing oncologists with a fascinating and immediately applicable compendium of vital information dealing with a well-balanced selection of common and uncommon cancers. At the heart of this book is the editor’s and authors’ desire to overcome the controversies and barriers to practice that usually emerge following the appearance of new data. In every section, the user is guided toward collaboration in ongoing clinical research – for example, via discussions of well-designed ongoing clinical trials in each specific area.\u003c\/p\u003e \u003cp\u003eDeveloped with both the teacher and learner in mind, this book also offers trainees and fellows an excellent opportunity to enhance their preparation for the ABIM oncology fellowship exam as well as for the oncology boards. It will also be an extremely useful tool for oncologists working toward the recertification exam. This comprehensive, beefy book includes hundreds of painstakingly developed multiple-choice and mini-case-based questions covering the principles of medical oncology, malignant hematology, surgical oncology, and radiation oncology. It also contains mini-cases and questions dealing with the biology, diagnosis, classification, staging, and multidisciplinary treatment of cancers at every anatomic site. The very latest topics are included, such as molecular techniques, targeted therapies, and translational cancer research. Concise but detailed answers are referenced to key journals and books, and evidence-based wherever possible. NCCN guidelines are also referenced as appropriate. With its powerful focus on take-home messages from and for actual clinical work, this book will help keep oncologists up to date, bridging the gaps between journal and reference literature, conferences, and their existing knowledge base.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003ci\u003eList of Contributors, x\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePreface, xxi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 1 Malignant Hematology and Hematopoietic Cell Transplantation\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 Acute Lymphoblastic Leukemia in Adults\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Diagnosis of acute lymphoblastic leukemia, 5\u003cbr\u003e \u003ci\u003eFrederick G. Behm, Agatha Bogard, Syed A. Abutalib, and Sujata S. Gaitonde\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Prognostic markers and models in acute lymphoblastic leukemia, 18\u003cbr\u003e \u003ci\u003eDieter Hoelzer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Management of B-cell acute lymphoblastic leukemia, 22\u003cbr\u003e \u003ci\u003eHady Ghanem, Hagop Kantarjian, Nitin Jain, and Elias Jabbour\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Management of T-cell acute lymphoblastic leukemia, 29\u003cbr\u003e \u003ci\u003eDaniel J. DeAngelo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Minimal residual disease in acute lymphoblastic leukemia, 35\u003cbr\u003e \u003ci\u003eMeir Wetzler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Hematopoietic cell transplantation in adult acute lymphoblastic leukemia, 40\u003cbr\u003e \u003ci\u003eNetanel A. Horowitz and Jacob M. Rowe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Acute Myeloid Leukemia in Adults\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7 Prognosis in acute myeloid leukemia: cytogenetics and beyond, 51\u003cbr\u003e \u003ci\u003eGordana Raca, Madina Sukhanova, and Lucy A. Godley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Induction therapy in acute myeloid leukemia, 58\u003cbr\u003e \u003ci\u003eTapan Kadia and Farhad Ravandi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Consolidation therapy in acute myeloid leukemia, 67\u003cbr\u003e \u003ci\u003eGregory K. Behbehani and Bruno C. Medeiros\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Management of acute promyelocytic leukemia, 71\u003cbr\u003e \u003ci\u003eEytan M. Stein and Martin S. Tallman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Minimal residual disease in acute myeloid leukemia, 76\u003cbr\u003e \u003ci\u003eHans Beier Ommen, Line Nederby, Marie Toft-Petersen, Charlotte Guldborg Nyvold, and Peter Hokland\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Relapsed and refractory acute myeloid leukemia, 82\u003cbr\u003e Stefan H. Faderl\u003c\/p\u003e \u003cp\u003e13 Hematopoietic cell transplantation in acute myeloid leukemia, 89\u003cbr\u003e \u003ci\u003eAntonio M. Jimenez and Stefan O. Ciurea\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Myelodysplastic Syndromes and Related Disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14 Pitfalls in the diagnosis of myelodysplastic syndromes, 99\u003cbr\u003e \u003ci\u003eJay Yang, Gail Bentley, and Charles A. Schiffer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Cytogenetics and prognostic models in myelodysplastic syndromes, 106\u003cbr\u003e \u003ci\u003eUma Borate and Harry P. Erba\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Management of myelodysplastic syndromes, 113\u003cbr\u003e \u003ci\u003eVu H. Duong, Alan F. List, and Rami S. Komrokji\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Management of therapy-related myeloid neoplasms, 120\u003cbr\u003e \u003ci\u003eJagoda K. Jasielec and Richard A. Larson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Hematopoietic cell transplantation in myelodysplastic syndromes, 126\u003cbr\u003e \u003ci\u003eAntonio Di Stasi, Armin Ghobadi, and Partow Kebriaei\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Acquired aplastic anemia, 131\u003cbr\u003e \u003ci\u003eValeria Visconte and Ramon V. Tiu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Myeloproliferative Neoplasms\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e20 Diagnostic approach in myeloproliferative neoplasms, 137\u003cbr\u003e \u003ci\u003eAyalew Tefferi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Chronic myeloid leukemia: chronic phase, 142\u003cbr\u003e \u003ci\u003eJerald P. Radich\u003c\/i\u003e\u003cbr\u003e \u003cbr\u003e 22 Blast crisis of chronic myeloid leukemia, 147\u003cbr\u003e \u003ci\u003eMichael J. Mauro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Chronic myeloid leukemia and pregnancy, 150\u003cbr\u003e \u003ci\u003eMichael J. Mauro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Polycythemia vera, 152\u003cbr\u003e \u003ci\u003eConstantine S. Tam and Srdan Verstovsek\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Essential thrombocytosis, 156\u003cbr\u003e \u003ci\u003ePaola Guglielmelli and Alessandro M. Vannucchi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Primary myelofibrosis, 162\u003cbr\u003e \u003ci\u003eAyalew Tefferi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Eosinophilic myeloproliferative disorders, 167\u003cbr\u003e \u003ci\u003eJason Gotlib\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Chronic myelomonocytic leukemia, 176\u003cbr\u003e \u003ci\u003eMrinal M. Patnaik\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Hematopoietic cell transplantation in chronic myeloid leukemia, 180\u003cbr\u003e \u003ci\u003eJerald P. Radich\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Hematopoietic cell transplantation in primary myelofibrosis, 187\u003cbr\u003e \u003ci\u003eIrum Khan and Damiano Rondelli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5 Chronic Lymphocytic and Other Leukemias\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e31 Prognostic markers and management of chronic lymphocytic leukemia, 195\u003cbr\u003e \u003ci\u003eCourtney D. DiNardo and Susan O’Brien\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Hematopoietic cell transplantation in chronic lymphocytic leukemia, 201\u003cbr\u003e \u003ci\u003eMichael R. Bishop\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Prolymphocytic leukemia, 207\u003cbr\u003e \u003ci\u003eClaire Dearden\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Hairy cell leukemia, 220\u003cbr\u003e \u003ci\u003eJustin M. Watts and Martin S. Tallman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6 Hodgkin Lymphoma\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e35 Management of classical Hodgkin lymphoma, 229\u003cbr\u003e \u003ci\u003eKristen Sanfi lippo and Nancy L. Bartlett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Nodular lymphocyte-predominant Hodgkin lymphoma, 235\u003cbr\u003e \u003ci\u003eDennis A. Eichenauer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Hematopoietic cell transplantation in Hodgkin lymphoma, 240\u003cbr\u003e \u003ci\u003eTsiporah Shore and Koen van Besien\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 7 Non-Hodgkin’s Lymphomas\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e38 Pitfalls in the diagnosis of non-Hodgkin’s lymphomas, 247\u003cbr\u003e \u003ci\u003eCarmen Barcena and Laurence de Leval\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e39 Follicular lymphoma, 257\u003cbr\u003e \u003ci\u003eMyron S. Czuczman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e40 Diffuse large B-cell lymphoma, 263\u003cbr\u003e \u003ci\u003eAndrew D. Zelenetz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e41 Mantle cell lymphoma, 270\u003cbr\u003e \u003ci\u003eStephen Smith and John Sweetenham\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e42 Marginal zone lymphoma, 275\u003cbr\u003e \u003ci\u003eSarah Rutherford, Wayne Tam, and Peter Martin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e43 Primary mediastinal large B-cell lymphoma, 282\u003cbr\u003e \u003ci\u003ePier Luigi Zinzani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e44 Burkitt lymphoma, 286\u003cbr\u003e \u003ci\u003eMark Roschewski and Wyndham Wilson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e45 Gray zone lymphoma, 290\u003cbr\u003e \u003ci\u003eCaron A. Jacobson and Ann S. LaCasce\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e46 Transformed lymphoma, 295\u003cbr\u003e \u003ci\u003eStephane Doucet and Jane N. Winter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e47 HIV-associated lymphoma, 304\u003cbr\u003e \u003ci\u003eKieron Dunleavy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e48 Primary CNS lymphoma, 308\u003cbr\u003e \u003ci\u003eNicholas A. Blondin, Joachim M. Baehring, and Fred H. Hochberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e49 Primary cutaneous lymphoma, 316\u003cbr\u003e \u003ci\u003eThomas M. Habermann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e50 Mycosis fungoides and Sézary syndrome, 323\u003cbr\u003e \u003ci\u003eStephane Dalle, Marie Perier-Muzet, Brigitte Balme, and Luc Thomas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e51 Hematopoietic cell transplantation in indolent non-Hodgkin’s lymphoma, 327\u003cbr\u003e \u003ci\u003eSaurabh Chhabra and Ginna G. Laport\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e52 Hematopoietic cell transplantation in diffuse large B-cell lymphoma, 332\u003cbr\u003e \u003ci\u003eSyed A. Abutalib and Istvan Redei\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e53 Hematopoietic cell transplantation in T-cell non-Hodgkin’s lymphomas, 339\u003cbr\u003e \u003ci\u003eLori S. Muffly and Sonali M. Smith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 8 Plasma Cell Neoplasms and Related Disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e54 Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance, 347\u003cbr\u003e \u003ci\u003eRobert A. Kyle\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e55 Risk stratification and response assessment in multiple myeloma and Waldenström’s macroglobulinemia, 352\u003cbr\u003e \u003ci\u003eSilvia Gentili and Sagar Lonial\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e56 Treatment of multiple myeloma, 358\u003cbr\u003e \u003ci\u003eCindy Varga, Claudia Paba Prada, Kenneth Anderson, and Paul Richardson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e57 Light-chain amyloidosis, 366\u003cbr\u003e \u003ci\u003eDavid C. Seldin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e58 Waldenström’s macroglobulinemia, 371\u003cbr\u003e \u003ci\u003eAnita D’Souza and Morie A. Gertz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e59 Autologous hematopoietic cell transplantation in multiple myeloma, 376\u003cbr\u003e \u003ci\u003eJean-Luc Harousseau and Mohamad Mohty\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e60 Allogeneic hematopoietic cell transplantation in multiple myeloma, 381\u003cbr\u003e \u003ci\u003eJasleen Randhawa, Veerpal Singh, and Parameswaran Hari\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 9 Special Issues in Hematology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e61 Role of PET scan in lymphomas, 391\u003cbr\u003e \u003ci\u003eMatthew A. Lunning and James O. Armitage\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e62 Radioimmunotherapy in lymphomas, 398\u003cbr\u003e \u003ci\u003eReem Karmali and Stephanie A. Gregory\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e63 Radiation oncology consultation for hematologic malignancies, 403\u003cbr\u003e \u003ci\u003eChris R. Kelsey and Leonard R. Prosnitz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 10 Special Issues in Hematopoietic Cell Transplantation\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e64 Donor and graft selection in allogeneic hematopoietic cell transplantation, 411\u003cbr\u003e \u003ci\u003eJose Leonel Ochoa-Bayona and Claudio Anasetti\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e65 Preparative regimens in allogeneic hematopoietic cell transplantation for malignant hematological\u003cbr\u003e diseases, 417\u003cbr\u003e \u003ci\u003eRobert J. Soiffer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e66 T-cell depletion in allogeneic hematopoietic cell transplantation, 421\u003cbr\u003e \u003ci\u003eJenna D. Goldberg and Miguel-Angel Perales\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e67 Prevention and treatment of relapse following hematopoietic cell transplantation, 426\u003cbr\u003e \u003ci\u003eRobert Chen, Sandra Thomas, and Stephen J. Forman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e68 Acute graft-versus-host disease, 432\u003cbr\u003e \u003ci\u003eAndrew C. Harris and John E. Levine\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e69 Chronic graft-versus-host disease, 438\u003cbr\u003e \u003ci\u003eCarrie L. Kitko and Daniel R. Couriel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2 Oncology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 Central Nervous System Tumors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e70 Primary brain tumors, 449\u003cbr\u003e \u003ci\u003eBarbara J. O’Brien and Mark R. Gilbert\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e71 Secondary brain and spinal cord tumors, 457\u003cbr\u003e \u003ci\u003eRimas V. Lukas, Patrik Gabikian, and Steven J. Chmura\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Head and Neck Cancers and Thoracic Malignancies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e72 Medical management of head and neck cancers, 467\u003cbr\u003e \u003ci\u003eTobenna Nwizu and David Adelstein\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e73 Endocrine malignancies, 476\u003cbr\u003e \u003ci\u003eAnn W. Gramza\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e74 Methodological and practical challenges for personalized therapies in non-small-cell lung cancer, 480\u003cbr\u003e \u003ci\u003eIgnacio I. Wistuba\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e75 Screening, staging, and stage I non-small-cell lung cancer, 486\u003cbr\u003e \u003ci\u003eTarek M. Mekhail\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e76 Stage II and III non-small-cell lung cancer, 493\u003cbr\u003e \u003ci\u003eGrzegorz Korpanty and Natasha B. Leighl\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e77 Recurrent and metastatic non-small-cell lung cancer and novel targets, 500\u003cbr\u003e \u003ci\u003eEvan Pisick and Ravi Salgia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e78 Small-cell lung cancer, 503\u003cbr\u003e \u003ci\u003eStephen V. Liu and Glen J. Weiss\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e79 Mesothelioma, 506\u003cbr\u003e \u003ci\u003eChristopher W. Towe and Harvey I. Pass\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Breast Cancer\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e80 Immunohistochemistry testing and beyond in breast cancer, 515\u003cbr\u003e \u003ci\u003eAlejandro A. Gru and D. Craig Allred\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e81 Prevention and adjuvant therapy in breast cancer, 523\u003cbr\u003e \u003ci\u003eFaithlore P. Gardner and Edith A. Perez\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e82 Preoperative systemic therapy for breast cancer, 532\u003cbr\u003e \u003ci\u003eVirginia Kaklamani and William J. Gradishar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e83 Recurrent and metastatic breast cancer, 540\u003cbr\u003e \u003ci\u003eDennis L. Citrin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e84 Special issues in the young and pregnant patient with breast cancer, 546\u003cbr\u003e \u003ci\u003eHatem A. Azim Jr. and Fedro A. Peccatori\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Gastrointestinal Oncology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e85 Early-stage esophageal and stomach cancers, 555\u003cbr\u003e \u003ci\u003eM. Naomi Horiba and Yixing Jiang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e86 Metastatic esophagogastric cancer: controversies, consensus, and new targets, 562\u003cbr\u003e \u003ci\u003eGeoffrey Y. Ku and David H. Ilson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e87 Early-stage colorectal cancer, 567\u003cbr\u003e \u003ci\u003eVaibhav Sahai and Al B. Benson III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e88 Recurrent and metastatic colorectal cancer: controversies, consensus, and new targets, 573\u003cbr\u003e \u003ci\u003eDavendra Sohal and Robert J. Pelley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e89 Pancreatic cancer, 581\u003cbr\u003e \u003ci\u003eKatherine Van Loon and Margaret Tempero\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e90 Hepatobiliary cancer, 590\u003cbr\u003e \u003ci\u003eKeith Stuart\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e91 Neuroendocrine tumors, 595\u003cbr\u003e \u003ci\u003eAnya Litvak and Leonard Saltz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e92 Transarterial liver-directed therapies in oncology, 601\u003cbr\u003e \u003ci\u003eDivyesh G. Mehta and Jeffery Choh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e93 Anal cancer, 606\u003cbr\u003e \u003ci\u003eRob Glynne Jones\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5 Genitourinary Oncology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e94 Renal cancer: tumor diversity, molecular taxonomy, and prognostic algorithms, 615\u003cbr\u003e \u003ci\u003eHenry J. Conter and Eric Jonasch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e95 Medical management of renal cancer, 621\u003cbr\u003e \u003ci\u003eGary R. MacVicar and Timothy M. Kuzel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e96 Medical management of bladder cancer, 628\u003cbr\u003e \u003ci\u003eGary R. MacVicar and Timothy M. Kuzel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e97 Prostate cancer: Screening, surveillance, prognostic algorithms and independent pathologic predictive\u003cbr\u003e parameters, 634\u003cbr\u003e \u003ci\u003eMegan G. Lockyer and Thomas M. Wheeler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e98 Medical management of prostate cancer, 638\u003cbr\u003e \u003ci\u003eElizabeth K. O’Donnell and Philip Kantoff\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e99 Germ cell tumors, 645\u003cbr\u003e \u003ci\u003eTimothy Gilligan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6 Skin Malignancies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e100 Medical management of melanoma, 653\u003cbr\u003e \u003ci\u003eAna M. Ciurea and Kim Margolin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e101 Nonmelanoma skin cancers, 661\u003cbr\u003e \u003ci\u003eDaniel Christiansen and Anna Sancho Clayton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 7 Gynecological Malignancies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e102 Ovarian cancer: neoadjuvant, adjuvant, and surgical issues, 669\u003cbr\u003e \u003ci\u003eAlpa M. Nick and Robert L. Coleman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e103 Ovarian cancer: second-line treatment strategies, 675\u003cbr\u003e \u003ci\u003eMaurie Markman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e104 Endometrial and cervical cancers, 681\u003cbr\u003e \u003ci\u003eMaurie Markman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 8 Sarcomas\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e105 Bone sarcomas, 689\u003cbr\u003e \u003ci\u003eNicole Larrier, William C. Eward, and Richard F. Riedel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e106 Soft tissue sarcomas, 696\u003cbr\u003e \u003ci\u003eNeeta Somaiah and Shreyaskumar Patel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 9 Multidisciplinary Approach: Consultation with Surgical Oncology Team\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e107 Surgical aspects of head and neck cancers, 707\u003cbr\u003e \u003ci\u003eConstance E.H. Teo and Randal S. Weber\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e108 Surgical aspects of thoracic malignancies, 711\u003cbr\u003e \u003ci\u003eAlbert S.Y. Chang, Thomas A. D’Amico, and David C. White\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e109 Surgical aspects of upper gastrointestinal cancers, 719\u003cbr\u003e \u003ci\u003eSabha Ganai and Mitchell C. Posner\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e110 Surgical aspects of pancreatic cancer, 723\u003cbr\u003e \u003ci\u003eAmanda B. Cooper, Ching-Wei D. Tzeng, and Matthew H.G. Katz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e111 Surgical aspects of hepatobiliary tumors, 729\u003cbr\u003e \u003ci\u003eSubhasis Misra and Leonidas Koniaris\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e112 Surgical aspects of lower gastrointestinal cancers, 735\u003cbr\u003e \u003ci\u003eAnthony J. Senagore\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e113 Surgical aspects of renal cancer, 739\u003cbr\u003e \u003ci\u003eMichael E. Woods and Matthew C. Raynor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e114 Surgical aspects of bladder cancer, 744\u003cbr\u003e \u003ci\u003eMichael B. Williams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e115 Surgical aspects of prostate cancer, 747\u003cbr\u003e \u003ci\u003ePeter Pinto\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e116 Surgical aspects of melanoma, 754\u003cbr\u003e \u003ci\u003eThomas Velancia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 10 Multidisciplinary Approach: Consultation with Radiation Oncology Team\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e117 Radiotherapy for head and neck cancers, 761\u003cbr\u003e \u003ci\u003eShiyu Song\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e118 Radiotherapy for ductal carcinoma in situ (DCIS), 767\u003cbr\u003e \u003ci\u003eBeryl McCormick\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e119 Radiotherapy for early-stage invasive breast cancer, 771\u003cbr\u003e \u003ci\u003eJulia White\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e120 Radiotherapy for thoracic malignancies, 778\u003cbr\u003e \u003ci\u003eMeredith E. Giuliani and Andrea Bezjak\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e121 Radiotherapy for gastrointestinal malignancies, 785\u003cbr\u003e \u003ci\u003eManisha Palta, Christopher Willett, and Brian Czito\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e122 Radiotherapy for genitourinary malignancies, 789\u003cbr\u003e \u003ci\u003eChristina H. Chapman and Curtiland Deville\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 11 Hereditary Cancer Syndromes and Genetic Testing in Oncology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e123 When to suspect hereditary cancer syndromes, 795\u003cbr\u003e \u003ci\u003eEmily Dalton and Kathy Schneider\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e124 Hereditary breast cancer syndromes, 800\u003cbr\u003e \u003ci\u003eKathy Schneider and Emily Dalton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e125 Genetic testing in gastrointestinal tumors, 804\u003cbr\u003e \u003ci\u003eKristen M. Shannon and Daniel C. Chung\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e126 Hereditary urogenital cancer syndromes, 810\u003cbr\u003e \u003ci\u003eMelanie Corbman and Eric Fowler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART 12 Special Issues in Hematology and Oncology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e127 Carcinoma of unknown primary (CUP), 817\u003cbr\u003e \u003ci\u003eIsabella C. Glitza and Gauri R. Varadhachary\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e128 Geriatric oncology, 822\u003cbr\u003e \u003ci\u003eNayana Kamath and Supriya Gupta Mohile\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e129 Nuts and bolts of cancer immunotherapy, 826\u003cbr\u003e \u003ci\u003eChristopher R. Heery and James L. Gulley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e130 Controversies related to oncology clinical trial development, 831\u003cbr\u003e \u003ci\u003eElihu H. Estey\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e131 PET scan in oncology, 835\u003cbr\u003e \u003ci\u003eShaunagh McDermott and Michael A. Blake\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e132 Hematopoietic growth factors, 841\u003cbr\u003e \u003ci\u003eLeAnn B. Norris, Jametta Magwood, and Charles L. Bennett\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e133 Anticoagulation issues in oncology, 844\u003cbr\u003e \u003ci\u003eSteven M. Corsello and Jean Marie Connors\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e134 Symptom management and palliative care, 851\u003cbr\u003e \u003ci\u003eRony Dev and Eduardo D. Bruera\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e135 Metabolic and nutritional issues in oncology, 860\u003cbr\u003e \u003ci\u003eJulia Fechtner, Carolyn Lammersfeld, Carol Ireton-Jones, and Pankaj Vashi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e136 Bone-related issues in oncology, 867\u003cbr\u003e \u003ci\u003eS. Mujtaba Rizvi, Helen Collins, and Alan Lipton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e137 Integrative medicine in oncology, 872\u003cbr\u003e \u003ci\u003eWeidong Lu and David S. Rosenthal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e138 Naturopathic medicine in oncology, 879\u003cbr\u003e \u003ci\u003eChristina M. Shannon, Tracey Thomas, and Shauna Birdsall\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e139 Anesthesiology consultation for localized cancer pain, 884\u003cbr\u003e \u003ci\u003eAbed Rahman, Magdalena Anitescu, and Raed Rahman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e140 Musculoskeletal care in oncology, 893\u003cbr\u003e \u003ci\u003eJames E. Rosenberg and Charles A. McDonald\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e141 Cancer survivorship and psychosocial issues in oncology, 896\u003cbr\u003e \u003ci\u003eJabeen Abutalib, Shahid Raza, and Laura Sunn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eIndex, 902\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eColor plate section facing p.522\u003c\/i\u003e\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Clinical \u0026amp; internal medicine [\u003ca title=\"See our other books on Clinical \u0026amp; internal medicine\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Clinical%20\u0026amp;%20internal%20medicine%20%5BMJ%5D%22\"\u003eMJ\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Brand New","offer_id":52417785528600,"sku":"9781118589212","price":119.39,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9781118589212.jpg?v=1784509300","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/cancer-consult-expertise-for-clinical-practice-paperback-softback-9781118589212","provider":"Freshly Printed Books","version":"1.0","type":"link"}